신경 자극 기기 시장 : 규모, 점유율, 동향 분석, 제품별, 용도별, 최종 용도별, 지역별, 부문 예측(2025-2033년)

Neurostimulation Devices Market Summary

The global neurostimulation devices market size was estimated at USD 5.80 billion in 2024 and is projected to reach USD 13.93 billion by 2033, growing at a CAGR of 10.29% from 2025 to 2033. The growth of the market is attributed due to the rising prevalence of neurological disorders, growing preference for minimally invasive therapies, and increasing demand for long-term pain management solutions.

Technological advancements such as closed-loop stimulation, MRI-compatible devices, and improved battery life enhance treatment precision and patient outcomes, driving wider clinical acceptance. In addition, expanding applications of neurostimulation in conditions such as chronic pain, epilepsy, Parkinson's disease, depression, and spinal cord injuries, along with supportive reimbursement policies in many regions, are further accelerating market growth.

Growing government funding for neuroscience research is a key driver of the neurostimulation devices market, as it accelerates the development of advanced neurostimulation technologies and expands therapeutic applications. By allocating capital to research programs, clinical trials, and innovation initiatives, governments enable a deeper understanding of neurological disorders and support breakthroughs in treatment approaches using neurostimulation. This financial backing fosters collaboration among researchers, clinicians, and medical device developers and encourages the commercialization of next-generation systems with improved safety, precision, and patient outcomes. Furthermore, government initiatives aimed at enhancing healthcare accessibility and reducing the cost burden of neurological care indirectly promote the adoption of neurostimulation therapies, expanding their reach to a broader patient base and fueling overall market growth.

Global Neurostimulation Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For the purpose of this study, Grand View Research has segmented the global neurostimulation devices market report on the basis of product, application, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Spinal Cord Stimulators
• Deep Brain Stimulators
• Sacral Nerve Stimulators
• Vagus Nerve Stimulators
• Gastric Electrical Stimulation
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Parkinson's Disease
• Chronic Pain
• Migraine
• Epilepsy
• Tremor
• Depression
• Urinary & Fecal Incontinence
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals & Ambulatory Surgery Centers (ASC)
• Clinics & Physiotherapy Centers
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
  • 1.5.1. Data for primary interviews in North America
  • 1.5.2. Data for primary interviews in Europe
  • 1.5.3. Data for primary interviews in Asia Pacific
  • 1.5.4. Data for primary interviews in Latin America
  • 1.5.5. Data for Primary interviews in MEA
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Neurostimulation Devices Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Government funding for research and development
    • 3.2.1.2. Technological advancements in neurostimulation devices
    • 3.2.1.3. Increasing prevalence of neurological disorders
    • 3.2.1.4. Growing reimbursement coverage
    • 3.2.1.5. Expanding applications
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. Complex regulatory framework
    • 3.2.2.2. Surgery-associated risk
• 3.3. Neurostimulation Devices Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Neurostimulation Devices Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Neurostimulation Devices Market: Product Movement Analysis, 2024 & 2033 (USD Million)
• 4.3. Global Neurostimulation Devices Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
• 4.4. Spinal Cord Stimulators
  • 4.4.1. Spinal cord stimulators market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. Deep Brain Stimulators
  • 4.5.1. Deep brain stimulators market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.6. Sacral Nerve Stimulators
  • 4.6.1. Sacral nerve stimulators market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.7. Vagus Nerve Stimulators
  • 4.7.1. Vagus nerve stimulators market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.8. Gastric Electrical Stimulation
  • 4.8.1. Gastric electrical stimulation market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.9. Others
  • 4.9.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Neurostimulation Devices Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Neurostimulation Devices Market: Application Movement Analysis, 2024 & 2033 (USD Million)
• 5.3. Global Neurostimulation Devices Market Size & Trend Analysis, by Application 2021 to 2033 (USD Million)
• 5.4. Parkinson's Disease
  • 5.4.1. Parkinson's disease market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Chronic Pain
  • 5.5.1. Chronic pain market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.6. Migraine
  • 5.6.1. Migraine market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.7. Epilepsy
  • 5.7.1. Epilepsy market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.8. Tremor
  • 5.8.1. Tremor market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.9. Depression
  • 5.9.1. Depression market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.10. Urinary & Fecal Incontinence
  • 5.10.1. Urinary & fecal incontinence market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.11. Others
  • 5.11.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Neurostimulation Devices Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Neurostimulation Devices Market: End use Movement Analysis, 2024 & 2033 (USD Million)
• 6.3. Global Neurostimulation Devices Market Size & Trend Analysis, by End use 2021 to 2033 (USD Million)
• 6.4. Hospitals & Ambulatory Surgery Centers (ASC)
  • 6.4.1. Hospitals & Ambulatory Surgery Centers (ASC) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Clinics & Physiotherapy Centers
  • 6.5.1. Clinics & physiotherapy centers market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Others
  • 6.6.1. Others market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Neurostimulation Devices Market: Regional Estimates & Trend Analysis by Product, Application and End Use

• 7.1. Regional Dashboard
• 7.2. Market Size and Trend Analysis, 2021 to 2033
• 7.3. North America
  • 7.3.1. North America neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Competitive scenario
    • 7.3.2.3. Regulatory framework
    • 7.3.2.4. Reimbursement scenario
    • 7.3.2.5. U.S. neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Competitive scenario
    • 7.3.3.3. Regulatory framework
    • 7.3.3.4. Reimbursement scenario
    • 7.3.3.5. Canada neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key country dynamics
    • 7.3.4.2. Competitive scenario
    • 7.3.4.3. Regulatory framework
    • 7.3.4.4. Reimbursement scenario
    • 7.3.4.5. Mexico neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Competitive scenario
    • 7.4.2.3. Regulatory framework
    • 7.4.2.4. Reimbursement scenario
    • 7.4.2.5. UK neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Competitive scenario
    • 7.4.3.3. Regulatory framework
    • 7.4.3.4. Reimbursement scenario
    • 7.4.3.5. Germany neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Competitive scenario
    • 7.4.4.3. Regulatory framework
    • 7.4.4.4. Reimbursement scenario
    • 7.4.4.5. France neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Competitive scenario
    • 7.4.5.3. Regulatory framework
    • 7.4.5.4. Reimbursement scenario
    • 7.4.5.5. Italy neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Competitive scenario
    • 7.4.6.3. Regulatory framework
    • 7.4.6.4. Reimbursement scenario
    • 7.4.6.5. Spain neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Competitive scenario
    • 7.4.7.3. Regulatory framework
    • 7.4.7.4. Reimbursement scenario
    • 7.4.7.5. Sweden neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Competitive scenario
    • 7.4.8.3. Regulatory framework
    • 7.4.8.4. Reimbursement scenario
    • 7.4.8.5. Denmark neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key country dynamics
    • 7.4.9.2. Competitive scenario
    • 7.4.9.3. Regulatory framework
    • 7.4.9.4. Reimbursement scenario
    • 7.4.9.5. Norway neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Reimbursement scenario
    • 7.5.2.5. China neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. Japan
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Reimbursement scenario
    • 7.5.3.5. Japan neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Competitive scenario
    • 7.5.4.3. Regulatory framework
    • 7.5.4.4. Reimbursement scenario
    • 7.5.4.5. India neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Competitive scenario
    • 7.5.5.3. Regulatory framework
    • 7.5.5.4. Reimbursement scenario
    • 7.5.5.5. South Korea neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Australia
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Competitive scenario
    • 7.5.6.3. Regulatory framework
    • 7.5.6.4. Reimbursement scenario
    • 7.5.6.5. Australia neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. Thailand
    • 7.5.7.1. Key country dynamics
    • 7.5.7.2. Competitive scenario
    • 7.5.7.3. Regulatory framework
    • 7.5.7.4. Reimbursement scenario
    • 7.5.7.5. Thailand neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. Brazil neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Argentina neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
• 7.7. Middle East and Africa
  • 7.7.1. Middle East and Africa neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. South Africa neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. Saudi Arabia
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. Saudi Arabia neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. UAE
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. UAE neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. Kuwait neurostimulation devices market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis by Key Market Participants
• 8.2. Company Categorization
• 8.3. Company Market Share Analysis, 2023
• 8.4. Company Heat Map Analysis
• 8.5. Strategy Mapping
  • 8.5.1. Expansion
  • 8.5.2. Mergers & Acquisition
  • 8.5.3. Partnerships & Collaborations
  • 8.5.4. New Product Launches
  • 8.5.5. Research And Development
  • 8.5.6. Company Profiles
  • 8.5.7. Abbott (St. Jude Medical)
    • 8.5.7.1. Company overview
    • 8.5.7.2. Financial performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic initiatives
  • 8.5.8. Medtronic
    • 8.5.8.1. Company overview
    • 8.5.8.2. Financial performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic initiatives
  • 8.5.9. Boston Scientific Corporation
    • 8.5.9.1. Company overview
    • 8.5.9.2. Financial performance
    • 8.5.9.3. Product Benchmarking
    • 8.5.9.4. Strategic initiatives
  • 8.5.10. Aleva Neurotherapeutics
    • 8.5.10.1. Company overview
    • 8.5.10.2. Financial performance
    • 8.5.10.3. Product Benchmarking
    • 8.5.10.4. Strategic initiatives
  • 8.5.11. Nexstim
    • 8.5.11.1. Company overview
    • 8.5.11.2. Financial performance
    • 8.5.11.3. Product Benchmarking
    • 8.5.11.4. Strategic initiatives
  • 8.5.12. LivaNova PLC
    • 8.5.12.1. Company overview
    • 8.5.12.2. Financial performance
    • 8.5.12.3. Product Benchmarking
    • 8.5.12.4. Strategic initiatives
  • 8.5.13. Neuropace Inc.
    • 8.5.13.1. Company overview
    • 8.5.13.2. Financial performance
    • 8.5.13.3. Product Benchmarking
    • 8.5.13.4. Strategic initiatives
  • 8.5.14. Nevro Corporation
    • 8.5.14.1. Company overview
    • 8.5.14.2. Financial performance
    • 8.5.14.3. Product Benchmarking
    • 8.5.14.4. Strategic initiatives
  • 8.5.15. electroCore, Inc.
    • 8.5.15.1. Company overview
    • 8.5.15.2. Financial performance
    • 8.5.15.3. Product Benchmarking
    • 8.5.15.4. Strategic initiatives
  • 8.5.16. Axonics, Inc.
    • 8.5.16.1. Company overview
    • 8.5.16.2. Financial performance
    • 8.5.16.3. Product Benchmarking
    • 8.5.16.4. Strategic initiatives
  • 8.5.17. Nalu Medical
    • 8.5.17.1. Company overview
    • 8.5.17.2. Financial performance
    • 8.5.17.3. Product Benchmarking
    • 8.5.17.4. Strategic initiatives
  • 8.5.18. Mainstay Medical
    • 8.5.18.1. Company overview
    • 8.5.18.2. Financial performance
    • 8.5.18.3. Product Benchmarking
    • 8.5.18.4. Strategic initiatives
  • 8.5.19. Saluda Medical Pty Ltd
    • 8.5.19.1. Company overview
    • 8.5.19.2. Financial performance
    • 8.5.19.3. Product Benchmarking
    • 8.5.19.4. Strategic initiatives
  • 8.5.20. Biotronik
    • 8.5.20.1. Company overview
    • 8.5.20.2. Financial performance
    • 8.5.20.3. Product Benchmarking
    • 8.5.20.4. Strategic initiatives
  • 8.5.21. MicroTransponder Inc.
    • 8.5.21.1. Company overview
    • 8.5.21.2. Financial performance
    • 8.5.21.3. Product Benchmarking
    • 8.5.21.4. Strategic initiatives
  • 8.5.22. tVNS Technologies GmbH
    • 8.5.22.1. Company overview
    • 8.5.22.2. Financial performance
    • 8.5.22.3. Product Benchmarking
    • 8.5.22.4. Strategic initiatives
  • 8.5.23. Laborie
    • 8.5.23.1. Company overview
    • 8.5.23.2. Financial performance
    • 8.5.23.3. Product Benchmarking
    • 8.5.23.4. Strategic initiatives